|
|
|
|
| Join Chief Editor Erin Harris for a special Cell & Gene Live discussion with Robert Bell, Ph.D., CSO at Ascidian Therapeutics, and Karen Kozarsky, Ph.D., Founder of Vector BioPartners . Together, they'll explore how capsid engineering affects transduction efficiency, the tradeoffs between tissue specificity and manufacturability, and what manufacturing teams need to know about real-world in vivo performance. Register for Solving Vector Yield Challenges in In Vivo CGT on July 7, 2026 at 11 AM ET. |
|
|
|
|
By Jose Saiz de Omeñaca | Restrictions and fear on the Hormuz Strait have fractured supply chains, especially for primary materials used in pharmaceutical packaging. | |
|
|
| 5 Operational Gaps To Avoid CGT Patient Risks | Article | Cencora | Examine five critical supply chain gaps in cell and gene therapy logistics that put patients at risk, from invisible operational burdens to reactive monitoring and fragmented coordination strategies. |
|
|
|
|
|
|
CLINICAL TRIALS SOLUTIONS |
|
|
|
| Connect With Cell & Gene: |
|
|
|
